<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968484</url>
  </required_header>
  <id_info>
    <org_study_id>PlaTiSep</org_study_id>
    <nct_id>NCT03968484</nct_id>
  </id_info>
  <brief_title>Platelet Transfusion in Sepsis Trial</brief_title>
  <official_title>Platelet Transfusion in Sepsis Trial (PlaTiSep)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelets are important mediators of an inflammatory response and a key component of the
      innate immune system to defend the human body against invading pathogens. However, little
      evidence exists regarding the number of platelets that should be used als transfusion
      threshold in septic patients. In this trial platelet transfusion will be performed with
      either &lt;50000/µl or &lt;20000/µl as a trigger.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    COVID-19 trials gained priority
  </why_stopped>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival in 90 day follow-up period</measure>
    <time_frame>90 days</time_frame>
    <description>overall survival at 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause mortality at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>overall survival at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resolution of shock</measure>
    <time_frame>5 days</time_frame>
    <description>time to normalization of lactate levels and end of vasopressor therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>28 days</time_frame>
    <description>length of stay on ICU ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of mechanical ventilation support</measure>
    <time_frame>28 days</time_frame>
    <description>time to extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal replacement therapy</measure>
    <time_frame>28 days</time_frame>
    <description>frequency and duration of renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding events</measure>
    <time_frame>28 days</time_frame>
    <description>bleeding events requiring transfusion during ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>28 days</time_frame>
    <description>Sepsis-related organ failure assessment score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>discharge location</measure>
    <time_frame>90 days</time_frame>
    <description>discharge to home, ward, rehabilitation unit, nursing home</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sepsis</condition>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>&lt;50.000/µl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfusion of platelets starting with a platelet count &lt;50.000/µl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&lt;20.000/µl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfusion of platelets starting with a platelet count &lt;20.000/µl</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>platelet transfusion</intervention_name>
    <description>Transfusion of platelets</description>
    <arm_group_label>&lt;20.000/µl</arm_group_label>
    <arm_group_label>&lt;50.000/µl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sepsis defined as alteration of SOFA score (Sepsis-related organ failure assessment
             score) &gt;2 points (Sepsis-3 definition)

          -  platelet count &lt;50.000/µl

        Exclusion Criteria:

          -  Age less than 18 years

          -  patients with immune thrombocytopenia

          -  major bleeding in the last 72 hours or ongoing major bleeding

          -  patient, surrogate or physician not committed to full intensive care support

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Rosenberger, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital Tübingen</affiliation>
  </overall_official>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

